Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anastrozole and Ecdysterone Interaction: Avoid | Peptide Database

Compound Profiles Anastrozole Aromatase Inhibitor | Estrogen Management Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Ecdysterone

Phytoecdysteroid | Natural Anabolic & Performance Enhancer

Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anastrozole with Ecdysterone?

Combining Anastrozole with Ecdysterone is not recommended. Both Anastrozole and Ecdysterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Ecdysterone safe together?

This combination carries significant risk. Both Anastrozole and Ecdysterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Ecdysterone?

Both Anastrozole and Ecdysterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Ecdysterone?

Anastrozole has a half-life of ~40-50 hours and Ecdysterone has a half-life of ~4-9 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching CJC/IPA Protocol — share findings, ask questions, and learn from real experiences A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation. CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.

Source: peptide-db.com ↗

Research Indications

FDA-approved for the treatment of major depressive disorder, though it is rarely used as a primary antidepressant today due to the availability of SSRIs and SNRIs with more favorable side effect profiles for daytime use. Antidepressant doses range from 150-400 mg/day, significantly higher than the doses used for sleep. The most common clinical use of trazodone today. Low doses (25-100 mg) at bedtime reduce sleep onset latency, improve sleep continuity, and enhance slow-wave sleep. Multiple studies support its efficacy, and it is the most frequently prescribed off-label medication for insomnia in the United States. Particularly valued because it avoids the dependence and rebound insomnia associated with benzodiazepines and Z-drugs. Extremely popular in the bodybuilding and PED community for managing sleep disruption caused by anabolic steroids, particularly trenbolone (19-nortestosterone derivatives). Trenbolone is notorious for causing severe insomnia and night sweats, and trazodone at 50-100 mg is one of the most reliable and accessible solutions. Its non-addictive profile makes it suitable for use throughout entire steroid cycles. Useful for patients whose insomnia is driven by anxiety or racing thoughts at bedtime. The 5-HT2A antagonism and mild anxiolytic properties help quiet mental activity without the cognitive impairment of benzodiazepines. Often added to an existing SSRI or SNRI regimen specifically to address insomnia. Low-dose trazodone at bedtime can complement a daytime antidepressant without significant drug interaction concerns at typical doses.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Pitavastatin is administered exclusively via the oral route as film-coated tablets in 1 mg, 2 mg, and 4 mg strengths. It can be taken at any time of day with or without food. Its 12-hour half-life is sufficient for once-daily dosing to maintain effective HMG-CoA reductase inhibition throughout the day. Oral bioavailability is approximately 51%, which is notably higher than most other statins. The drug undergoes minimal CYP450 metabolism — it is primarily metabolized via glucuronidation (UGT1A3, UGT2B7) and is largely excreted unchanged in bile. This metabolic profile is the foundation of its low drug interaction potential. On-Cycle Lipid Management (AAS Use) 2-4 mg/day Once daily Oral Low-Interaction Statin Therapy Standard Hyperlipidemia (Non-AAS) 1-4 mg/day

Source: peptide-db.com ↗
Side effects

Common Side Effects

Injection site reactions (redness, mild irritation) Potential transient hypotension due to vasodilatory effects

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides